May 16 2013 – End Of Day Biotech Wrap-up

A lot of movers today and most were deep in the red. A lot of the moves were ASCO stocks selling off after the abstracts were released last night but.

May 15 2013 – End Of Day Biotech Wrap-up

Well, this is my first daily rundown for subscribers and while many of you have received these as emails, this might be new for others. In general, I like to.

Some highlights from Day 1 at Needham

The 12th Annual Needham Healthcare Conference began today with a number of presentations by widely biotech companies. Below we have a slideshow of the summary slides from companies that we.

ARIA – Ariad: Overvalued

Investors have high expectations for Ariad’s recently approved drug Iclusig. The tyrosine kinase inhibitor performed well in a pivotal Phase II of resistant/intolerant CML and Ph+ ALL patients. The successful.

Thursday at the JP Morgan Healthcare Conference

With the JP Morgan Healthcare Conference wrapped up, I wanted to highlight some notes from the Thursday session. I tried to keep them as concise as possible. We will say.

Upcoming medical conferences(September thru October)

With the summer almost over, we want to highlight some of the major medical meetings that will be pivotal events for many companies. September thru early December is ripe with.

ALNY TKMR – Updates on Alnylam and Tekmira

This post will provide a few updates from a number of recent presentations by Alnylam $ALNY (First Quarter 2012 earnings call and conference call regarding ALN-RSV data) and Tekmira $TKMR.

Cubist Settles Patent Lawsuit- Reader Questions

First off, Cubist has just settled with Teva over their patent litigation that will prevent Teva from entering the market until 2018. More details on that later. I got a.